Intra-Cellular Therapies Inc(ITCI)stock report

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company’s bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer’s Disease (AD).

ITCI pinelines are strong.

Finance:
Q3 2019(9/30/19): Cash 255M. Loss 34.72M

EPS and Sales:
https://finance.yahoo.com/quote/ITCI/financials?p=ITCI

Date EPS % last year % last quarter
2018.12.31 -2.84 -33.96% 35.89%
2019.3.31 -0.63 3.08% 77.82%
2019.6.31 -1.31 1.50% -5.00%
2019.9.30 -1.94 7.18% -48.09%

 

Sale:0

Insider Transactions:
http://insidercow.com/history/company.jsp?company=ITCI&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/ITCI/institutional-ownership/

2019.12.09:
Total institutions: 156,no change
Shares hold: 42835.5k shares. no change
shares% hold: 77.51%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/ITCI/price-targe

* News:

2020.01.07: Intra-Cellular Therapies Prices Public Offering of Common Stock at $29.50

2019.12.24: Investors flock to neuro drug makers after FDA approves new schizophrenia drug

2019.12.23: FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults

Leave a Reply